News

Pfizer announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly

The company submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg). The company submitted its MAA in the US several weeks

Jardiance can now be used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes (T2D) mellitus and cardiovascular disease (CVD). The agency’s decision

The EC’s approval follows a positive opinion in October from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). Earlier this year, Agilis received Orphan Drug

Pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that may play a role in depression. Massachusetts General Hospital (MGH) Department of Psychiatry executive vice

Fast Track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and address an unmet medical need. The designation enables

The partnership will identify and develop bicyclic peptides, Bicycles, a novel class of small molecule medicines designed to overcome several limitations of existing drug modalities. The deal tasks Bicycle with identifying bicyclic peptides

The collaboration integrates cognitive computing capabilities of IBM Watson with Pfizer’s scientific know how to help scientists generate meaningful insights. Pfizer will be the first company to use

The acquisition is expected to expand the UK based Heptares’ intellectual assets and platform for structure-based drug design and development centred on G protein-coupled receptors (GPCRs). Considered to